betnovate n cream kreem
glaxo wellcome uk limited trading as glaxo wellcome operations - beetametasoon+neomütsiin - kreem - 1mg+5mg 1g 15g 1tk
fucicort kreem
scandic pharma sia - beetametasoon+fusidiinhape - kreem - 1mg+20mg 1g 15g 1tk
fucicort kreem
leo pharma a/s - beetametasoon+fusidiinhape - kreem - 1mg+20mg 1g 15g 1tk
fucicort lipid kreem
leo pharma a/s - beetametasoon+fusidiinhape - kreem - 1mg+20mg 1g 30g 1tk; 1mg+20mg 1g 60g 1tk; 1mg+20mg 1g 5g 1tk; 1mg+20mg 1g 15g 1tk
betafuse geel
norbrook laboratories (ireland) limited - beetametasoon+fusidiinhape - geel - 1mg+5mg 1g 15g 1tk; 1mg+5mg 1g 30g 1tk
isaderm geel
dechra veterinary products a/s - beetametasoon+fusidiinhape - geel - 1mg+5mg 1g 30g 1tk
fucicort kreem
ideal trade links uab - beetametasoon+fusidiinhape - kreem - 1mg+20mg 1g 20g 1tk; 1mg+20mg 1g 15g 1tk
diprogenta salv
schering-plough labo - beetametasoon+gentamütsiin - salv - 0,5mg+1mg 1g 50g 1tk
sunitinib accord
accord healthcare s.l.u. - sunitiniib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastilised ained - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
entecavir accord
accord healthcare s.l.u. - entecavir - b-hepatiit, krooniline - viirusevastased ravimid süsteemseks kasutamiseks - entecavir accord is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: , compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis. , dekompenseeritud maksahaigus. nii hüvitada ja dekompenseeritud maksahaigus, see näidustus põhineb kliiniliste uuringute andmed nucleoside naiivne patsientidel hbeag positiivse ja hbeag negatiivne hbv infektsioon. lamivudiin-refraktaarse hepatiit b patsientide puhul. entecavir kokkuleppel on näidustatud ka ravi kroonilise hbv nakkuse nucleoside naiivne pediaatrilised patsiendid alates 2 kuni.